Laporte Kathleen’s recent SEC Form 4 filings reveal a predominantly selling bias, with $123,409.12 in total sales compared to $88,977.38 in purchases across 38 transactions. The most notable sale occurred on September 8, 2025, when Laporte divested shares of PRPO (Precipio, Inc.) for $123,409.12, marking the largest single transaction in the dataset. This contrasts with smaller acquisitions, including a $12,499.38 purchase of PRPO on October 15, 2025, and a $63,998 acquisition of QTTB (Q32 Bio Inc.) on January 15, 2026. The activity suggests a shift toward reducing exposure to PRPO while selectively adding positions in QTTB, though the latter remains a smaller component of the overall trading pattern.
Laporte’s transactions span multiple tickers, including BOLT (Bolt Biotherapeutics), ETNB (89bio, Inc.), and CERO (CERo Therapeutics Holdings), though many of these filings reflect negligible or zero-dollar value adjustments, likely tied to derivative transactions or grants. The most recent activity—a $12,480 PRPO acquisition alongside the QTTB purchase in January 2026—indicates a continued but measured engagement with biotech and pharmaceutical equities. The absence of recent sales beyond the September 2025 PRPO divestment suggests a period of consolidation, though the historical sell-heavy trend remains a defining feature of Laporte’s trading history.
AI-assisted summary